Xilio Therapeutics, Inc.

NasdaqGS:XLO Stock Report

Market Cap: US$40.4m

Xilio Therapeutics Management

Management criteria checks 1/4

Xilio Therapeutics' CEO is Rene Russo, appointed in May 2019, has a tenure of 5.5 years. total yearly compensation is $3.00M, comprised of 19.9% salary and 80.1% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $184.61K. The average tenure of the management team and the board of directors is 1.4 years and 3.8 years respectively.

Key information

Rene Russo

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage19.9%
CEO tenure5.5yrs
CEO ownership0.5%
Management average tenure1.4yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth

Oct 25
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth

Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation

We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

Aug 11
We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Rene Russo's remuneration changed compared to Xilio Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$63m

Jun 30 2024n/an/a

-US$66m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$3mUS$598k

-US$76m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$84m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$2mUS$575k

-US$88m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$82m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$5mUS$485k

-US$76m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$75m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$450k

-US$55m

Compensation vs Market: Rene's total compensation ($USD3.00M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Rene's compensation has increased whilst the company is unprofitable.

CEO

Rene Russo (49 yo)

5.5yrs

Tenure

US$2,999,910

Compensation

Dr. Rene Russo, BCPS, PharmD., serves as Director at Celsius Therapeutics, Inc. since May 2020. Since May 2019, Dr. Russo has been the Chief Executive Officer and Director of Xilio Therapeutics, Inc., (for...

Leadership Team

NamePositionTenureCompensationOwnership
Rene Russo
President5.5yrsUS$3.00m0.46%
$ 184.6k
Christopher Frankenfield
Chief Operating Officer1.3yrsUS$1.86m0%
$ 0
Katarina Luptakova
Chief Medical Officer1.2yrsUS$932.17k0%
$ 0
Kevin Brennan
Senior VP of Finance & Accounting1.6yrsno datano data
Uli Bialucha
Chief Scientific Officer2.3yrsno datano data
Scott Coleman
Chief Development Officer1.2yrsno datano data

1.4yrs

Average Tenure

48.5yo

Average Age

Experienced Management: XLO's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Rene Russo
President5.5yrsUS$3.00m0.46%
$ 184.6k
Paul Clancy
Non-Employee Independent Chairman4.3yrsUS$96.77k0%
$ 0
Daniel Curran
Independent Director3.9yrsno datano data
Sara Bonstein
Independent Director3.3yrsUS$76.77k0%
$ 0
Christina Rossi
Independent Director3.6yrsUS$78.05k0%
$ 0
Jason J. Luke
Member of Scientific Advisory Board3.8yrsno datano data
Deborah Charych
Member of Scientific Advisory Boardno datano datano data
Christopher Hunter
Member of Scientific Advisory Boardno datano datano data
Anthony O'Donoghue
Member of Scientific Advisory Boardno datano datano data
Jamie Spangler
Member of Scientific Advisory Board3.8yrsno datano data
Kwok-Kin Wong
Member of Scientific Advisory Board3.8yrsno datano data
Andy Minn
Member of Scientific Advisory Board3.8yrsno datano data

3.8yrs

Average Tenure

53yo

Average Age

Experienced Board: XLO's board of directors are considered experienced (3.8 years average tenure).